Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Atrium Therapeutics, Inc.

NASDAQ: RNA · Life Sciences · 6 alerts · CIK 2093101

Atrium Therapeutics, Inc. stories on ALFA USA NewsRead the news →
Share price
$6.43Close, Nov 16
Market cap
$139M
Shares outstanding
21.57MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Atrium Therapeutics, Inc. filings on SEC EDGAR ↗

4:18 PM ET 10-Q
Financial Results

Atrium Therapeutics Q3 2026 Results: Net Loss of $4.27M, Loss Widens

Atrium Therapeutics reported a net loss of $41.1 million for the nine months ended September 30, 2026, compared to $20.4 million in the prior year period, driven by a significant increase in general and administrative expenses following its spin-off. The company ended the quarter with $232.1 million in cash, cash equivalents, and short-term investments, bolstered by a $313.4 million transfer from its former parent company.

Key figure
Net loss $4.27M
4:17 PM ET 8-K
Financial Results

Atrium Therapeutics Financial Results

Atrium Therapeutics reported third quarter 2026 financial results, highlighting the dosing of the first patient in its Phase 1/2 clinical trial for ATR 1072. The company also closed a $50 million private placement, extending its cash runway through 2028 with a pro-forma cash balance of $293.6 million.

Term
Q3 2026

“The last eight months have marked many firsts for Atrium, building toward our transition to a clinical stage company with the initiation of Corventis, the first clinical trial ever to target the root cause of PRKAG2 syndrome.”

Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics

“Our $50 million private placement with leading institutional investors extends our cash runway through 2028. With ~$290 million on our balance sheet, we are well positioned to deliver on our upcoming milestones.”

Brendan Winslow, Chief Financial Officer of Atrium Therapeutics
6:48 AM ET 8-K
Clinical Trial Data

Atrium Therapeutics Clinical Trial Data

Atrium Therapeutics announced nonclinical data for its lead therapy ATR 1072 showing reversal of cardiac glycogen accumulation and improvement in hypertrophy in a mouse model of PRKAG2 syndrome. The company plans to present these findings at the American Heart Association Scientific Sessions 2026 and expects initial Phase 1/2 clinical proof-of-concept data in the second half of 2027.

8:56 AM ET 8-K
Business Update

Atrium Therapeutics Business Update

Atrium Therapeutics announced the first patient has been dosed in its Phase 1/2 Corventis clinical trial evaluating ATR 1072 for the treatment of PRKAG2 syndrome. This represents the first interventional clinical trial for this rare genetic cardiomyopathy, with initial proof-of-concept data expected in the second half of 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.